CD19 and diffuse large B-cell lymphoma: Recently, Fehse et al. employed ddPCR also to detect and quantify transgenic CAR-T (chimeric antigen receptor T) cells transfused in vivo in refractory/relapsed Diffuse Large B-Cell Lymphomas (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL) patients treated with axicabtagene ciloleucel (Axi-cel) CD19-CAR-T cells [151].